Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Perera, N. Papa, M. Roberts, Michael Williams, C. Udovicich, I. Vela, D. Christidis, D. Bolton, M. Hofman, N. Lawrentschuk, D. Murphy (2020)
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.European urology
N. Guberina, P. Hetkamp, H. Ruebben, W. Fendler, Johannes Grueneisen, S. Suntharalingam, J. Kirchner, L. Puellen, N. Harke, J. Radtke, L. Umutlu, B. Hadaschik, K. Herrmann, M. Forsting, A. Wetter (2019)
Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of ReferenceMolecular Imaging and Biology, 22
A. Becker, K. Chaitanya, K. Schawkat, Urs Muehlematter, A. Hötker, E. Konukoglu, O. Donati (2019)
Variability of manual segmentation of the prostate in axial T2-weighted MRI: A multi-reader study.European journal of radiology, 121
A. Morsing, M. Hildebrandt, M. Vilstrup, S. Wallenius, O. Gerke, H. Petersen, A. Johansen, T. Andersen, P. Høilund-Carlsen (2019)
Hybrid PET/MRI in major cancers: a scoping reviewEuropean Journal of Nuclear Medicine and Molecular Imaging
T. Lengana, I. Lawal, T. Boshomane, G. Popoola, K. Mokoala, E. Moshokoa, A. Maes, N. Mokgoro, C. Wiele, M. Vorster, M. Sathekge (2018)
68Ga‐PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?Clinical Genitourinary Cancer, 16
J. Rogasch, H. Cash, S. Zschaeck, S. Elezkurtaj, W. Brenner, B. Hamm, M. Makowski, H. Amthauer, C. Furth, A. Baur (2018)
Ga‐68‐PSMA PET/CT in treatment‐naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA‐positive metastases?The Prostate, 78
H. Vargas, Rachel Schor-Bardach, N. Long, Anna Kirzner, J. Cunningham, D. Goldman, C. Moskowitz, Ramon Sosa, E. Sala, D. Panicek, H. Hricak (2016)
Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosisAbdominal Radiology, 42
吴涵潇, Han-xiao Wu, 宋子健, Ziye Song, 程超, Cheng Chao, 阳青松, Qin Yang, 陈锐, Chen Rui, 高旭, Gaojun Xu (2021)
68 Ga-PSMA-11 PET-CT与全身磁共振成像诊断前列腺癌远处转移的效能比较
S. Woo, C. Suh, S. Kim, J. Cho, S. Kim (2018)
The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis.AJR. American journal of roentgenology, 210 3
D. Shetty, D. Patel, K. Le, C. Bui, R. Mansberg (2018)
Pitfalls in Gallium-68 PSMA PET/CT Interpretation—A Pictorial ReviewTomography, 4
Urs Muehlematter, I. Burger, A. Becker, K. Schawkat, A. Hötker, C. Reiner, Julian Müller, N. Rupp, J. Rüschoff, D. Eberli, O. Donati (2019)
Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.Radiology
M. Mayerhoefer, H. Prosch, L. Beer, D. Tamandl, T. Beyer, C. Hoeller, D. Berzaczy, M. Raderer, M. Preusser, M. Hochmair, B. Kiesewetter, C. Scheuba, A. Ba-Ssalamah, G. Karanikas, Julia Kesselbacher, G. Prager, K. Dieckmann, S. Polterauer, Michael Weber, I. Rausch, Bernhard Brauner, H. Eidherr, W. Wadsak, A. Haug (2019)
PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerationsEuropean Journal of Nuclear Medicine and Molecular Imaging, 47
M. Mansbridge, E. Chung, H. Rhee (2019)
The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological LimitationsMedical Sciences, 7
Von Eyben (2018)
(68)Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysisEur Urol Focus, 4
B. Grubmüller, P. Baltzer, S. Hartenbach, D. D’andrea, T. Helbich, A. Haug, G. Goldner, W. Wadsak, S. Pfaff, M. Mitterhauser, T. Balber, N. Berroterán-Infante, M. Grahovac, J. Babich, C. Seitz, G. Kramer, M. Susani, P. Mazal, L. Kenner, S. Shariat, M. Hacker, M. Hartenbach (2018)
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical ImpactClinical Cancer Research, 24
M. Hofman, D. Murphy, S. Williams, T. Nzenza, A. Herschtal, R. Lourenco, D. Bailey, R. Budd, R. Hicks, R. Francis, N. Lawrentschuk (2018)
A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocolBJU International, 122
M. Piert, J. Montgomery, L. Kunju, J. Siddiqui, Virginia Rogers, Thekkelnaycke Rajendiran, T. Johnson, X. Shao, M. Davenport (2016)
18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate BiopsiesThe Journal of Nuclear Medicine, 57
(2018)
Potential impact of (68)Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning
M. Hofman, R. Hicks, T. Maurer, M. Eiber (2018)
Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.Radiographics : a review publication of the Radiological Society of North America, Inc, 38 1
(2018)
The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study
S. Dewes, K. Schiller, K. Sauter, M. Eiber, T. Maurer, M. Schwaiger, J. Gschwend, S. Combs, G. Habl (2016)
Integration of 68 Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
F. Cantiello, Vincenzo Gangemi, G. Cascini, F. Calabria, M. Moschini, M. Ferro, G. Musi, S. Butticè, A. Salonia, A. Briganti, R. Damiano (2017)
Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.Urology, 106
Jingliang Zhang, Shuai Shao, Peng Wu, Daliang Liu, Bo Yang, Donghui Han, Yu Li, Xiaoyu Lin, Wei Song, Milin Cao, Jing Zhang, Fei Kang, Weijun Qin, Jing Wang (2019)
Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomogramsEuropean Journal of Nuclear Medicine and Molecular Imaging, 46
Wu (2019)
Diagnostic performance of (6)(8)gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysisWorld J Mens Health
T. Hope, Jeremy Goodman, I. Allen, J. Calais, W. Fendler, P. Carroll (2018)
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by HistopathologyThe Journal of Nuclear Medicine, 60
Sterzing (2016)
(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patientsEur J Nucl Med Mol Imaging, 43
Yaxley (2019)
Risk of metastatic disease on (68) Ga-PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancerBJU Int, 124
Hoffmann (2017)
Diagnostic performance of (68)Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with (18)FEC PET/CTOncotarget, 8
B. Turkbey, A. Rosenkrantz, M. Haider, A. Padhani, G. Villeirs, K. Macura, C. Tempany, P. Choyke, F. Cornud, D. Margolis, H. Thoeny, S. Verma, J. Barentsz, J. Weinreb (2019)
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.European urology
M. Nørgaard, A. Jensen, J. Jacobsen, Kara Cetin, J. Fryzek, H. Sørensen (2010)
Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).The Journal of urology, 184 1
F. Giesel, B. Hadaschik, J. Cardinale, J. Radtke, M. Vinsensia, W. Lehnert, C. Kesch, Y. Tolstov, S. Singer, Niels Grabe, S. Duensing, M. Schäfer, O. Neels, W. Mier, U. Haberkorn, K. Kopka, C. Kratochwil (2016)
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 44
J. Weinreb, J. Barentsz, P. Choyke, F. Cornud, M. Haider, K. Macura, D. Margolis, M. Schnall, F. Shtern, C. Tempany, H. Thoeny, S. Verma (2016)
PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.European urology, 69 1
Kalapara (2019)
Detection and localisation of primary prostate cancer using (68) Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimensBJU Int
D. Pizzuto, Julian Müller, Urs Mühlematter, N. Rupp, A. Töpfer, A. Mortezavi, H. Nagel, B. Kranzbühler, D. Eberli, I. Burger (2018)
The central zone has increased 68Ga-PSMA-11 uptake: “Mickey Mouse ears” can be hot on 68Ga-PSMA-11 PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 45
Anna Ringheim, G. Neto, K. Martins, Taise Vitor, M. Cunha, R. Baroni (2018)
Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patientsAnnals of Nuclear Medicine, 32
(2017)
The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer
C. Spick, K. Herrmann, J. Czernin (2016)
18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 PatientsThe Journal of Nuclear Medicine, 57
A. Sheridan, S. Nath, J. Syed, S. Aneja, P. Sprenkle, J. Weinreb, Michael Spektor (2017)
Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.AJR. American journal of roentgenology, 210 2
(2015)
68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer
A. Afshar-Oromieh, A. Afshar-Oromieh, U. Haberkorn, U. Haberkorn, H. Schlemmer, M. Fenchel, M. Eder, M. Eisenhut, B. Hadaschik, A. Kopp-Schneider, Matthias Röthke (2014)
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 41
A. Briganti, N. Passoni, M. Ferrari, U. Capitanio, N. Suardi, A. Gallina, L. Pozzo, M. Picchio, V. Girolamo, A. Salonia, Liugi Gianolli, C. Messa, P. Rigatti, F. Montorsi (2010)
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.European urology, 57 4
O. Catalano, B. Rosen, D. Sahani, P. Hahn, A. Guimaraes, M. Vangel, E. Nicolai, A. Soricelli, M. Salvatore (2013)
Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients--a hypothesis-generating exploratory study.Radiology, 269 3
(2019)
PSMA PET/CT improves initial staging and management plan of patients with high-risk prostate cancer
(2018)
One-stop shop whole-body (68)Ga-PSMA-11 PET/MRI compared to clinical nomograms for preoperative T- and N-staging of high-risk prostate cancer
A. Hövels, R. Heesakkers, E. Adang, G. Jager, S. Strum, Y. Hoogeveen, J. Severens, J. Barentsz (2008)
The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.Clinical radiology, 63 4
(2016)
Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer
E. Demirci, L. Kabasakal, O. Şahin, Elife Akgün, Mehmet Gültekin, Tunkut Doğanca, M. Tuna, C. Öbek, M. Kılıç, T. Esen, A. Kural (2018)
Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?Nuclear Medicine Communications, 40
(2015)
- specific membrane antigen - based imaging in prostate cancer : impact on clinical decision making process
A. Paschalis, Beshara Sheehan, R. Riisnaes, D. Rodrigues, B. Gurel, C. Bertan, A. Ferreira, Maryou Lambros, G. Seed, W. Yuan, D. Dolling, J. Welti, A. Neeb, S. Sumanasuriya, P. Rescigno, D. Bianchini, N. Tunariu, S. Carreira, A. Sharp, W. Oyen, J. Bono (2019)
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerEuropean Urology, 76
(2020)
68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer
Nadine Woythal, R. Arsenić, C. Kempkensteffen, K. Miller, J. Janssen, K. Huang, M. Makowski, W. Brenner, V. Prasad (2017)
Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate CancerThe Journal of Nuclear Medicine, 59
S. Koerber, Leon Will, C. Kratochwil, M. Haefner, H. Rathke, C. Kremer, J. Merkle, K. Herfarth, K. Kopka, P. Choyke, T. Holland-Letz, U. Haberkorn, J. Debus, F. Giesel (2018)
68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 PatientsThe Journal of Nuclear Medicine, 60
L. Budäus, Sami-Ramzi Leyh-Bannurah, G. Salomon, U. Michl, H. Heinzer, H. Huland, M. Graefen, T. Steuber, C. Rosenbaum (2016)
Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.European urology, 69 3
Burçak Yılmaz, R. Turkay, Y. Çolakoğlu, H. Baytekin, N. Ergul, S. Şahin, V. Tuğcu, E. Inci, A. Taşçı, T. Çermik (2019)
Comparison of preoperative locoregional Ga‐68 PSMA‐11 PET‐CT and mp‐MRI results with postoperative histopathology of prostate cancerThe Prostate, 79
J. Yaxley, S. Raveenthiran, F. Nouhaud, Hemamali Samartunga, Anna Yaxley, G. Coughlin, B. Delahunt, L. Egevad, L. McEwan, D. Wong (2019)
Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node PathologyThe Journal of Urology, 201
S. Park, C. Zacharias, Caitlyn Harrison, Richard Fan, C. Kunder, N. Hatami, F. Giesel, P. Ghanouni, B. Daniel, A. Loening, G. Sonn, A. Iagaru (2018)
Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.Radiology, 288 2
(2016)
Simultaneous (68)Ga-PSMA HBEDCC PET/MRI improves the localization of primary prostate cancer
Van Leeuwen (2017)
Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancerBJU Int, 119
I. Berger, I. Berger, C. Annabattula, J. Lewis, D. Shetty, J. Kam, F. Maclean, M. Arianayagam, B. Canagasingham, R. Ferguson, M. Khadra, M. Khadra, R. Ko, M. Winter*, H. Loh, C. Varol (2018)
68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathologyProstate Cancer and Prostatic Diseases, 21
Seong-Jang Kim, Sang-Woo Lee, H. Ha (2018)
Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-AnalysisUrologia Internationalis, 102
L. Lindenberg, M. Ahlman, B. Turkbey, E. Mena, P. Choyke (2016)
Evaluation of Prostate Cancer with PET/MRIThe Journal of Nuclear Medicine, 57
F. Giesel, H. Fiedler, M. Stefanova, F. Sterzing, M. Rius, K. Kopka, J. Moltz, A. Afshar-Oromieh, P. Choyke, U. Haberkorn, C. Kratochwil (2015)
PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 42
(2013)
Comparison of integrated wholebody [11C]choline PET/MR with PET/CT in patients with prostate cancer
A. Kalapara, T. Nzenza, H. Pan, Z. Ballok, S. Ramdave, R. O’sullivan, A. Ryan, M. Cherk, M. Hofman, B. Konety, N. Lawrentschuk, D. Bolton, D. Murphy, J. Grummet, M. Frydenberg (2020)
Detection and localisation of primary prostate cancer using 68gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathologyBJU International, 126
T. Maurer, J. Gschwend, I. Rauscher, M. Souvatzoglou, B. Haller, G. Weirich, H. Wester, M. Heck, H. Kübler, A. Beer, M. Schwaiger, M. Eiber (2016)
Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.The Journal of urology, 195 5
P. Donato, M. Roberts, A. Morton, S. Kyle, G. Coughlin, R. Esler, N. Dunglison, R. Gardiner, J. Yaxley (2018)
Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 46
Daniela Ferraro, N. Rupp, O. Donati, M. Messerli, D. Eberli, I. Burger (2019)
68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue.Clinical Nuclear Medicine
(2019)
68)Ga-PSMA-PET/CT in comparison with (18)F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study
T. Pyka, Shozo Okamoto, Marielena Dahlbender, R. Tauber, M. Retz, M. Heck, N. Tamaki, M. Schwaiger, T. Maurer, M. Eiber (2016)
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 43
Maximum intensity projection (A) and axial 68 Ga-PSMA PET/CT fusion (B-D) and CT (E-G) images of a 61-year-old patient referred for a PSMA PET for staging of prostate cancer [cT2a, PSA 56 ng/mL
N. Schmidt-Hegemann, C. Eze, Minglun Li, P. Rogowski, C. Schaefer, C. Stief, A. Buchner, C. Zamboglou, W. Fendler, U. Ganswindt, C. Cyran, P. Bartenstein, C. Belka, H. Ilhan (2018)
Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective AnalysisThe Journal of Nuclear Medicine, 60
(2020)
Risk of metastatic disease
van Kalmthout (2019)
Prospective validation of gallium-68 prostate specific membrane antigen-positron emission tomography/computerized tomography in primary staging of patients with prostate cancerJ Urol
(2018)
( 68 ) Ga - PSMA - PET / CT staging prior to definitive radiation treatment for prostate cancer
M. Basha, M. Hamed, O. Hussein, T. El-Diasty, Y. Abdelkhalek, Y. Hussein, Ahmed Alasamer, Heba Mohamed, Dalia Deen, E. Tantawy, Maha Metwally, Mohamed Zaitoun, S. Aly, Jehan Altohamy, A. Mohamed, Amira Afifi, O. Harb (2019)
68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreementAbdominal Radiology, 44
Downloaded from http://journals.lww.com/topicsinmri by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/05/2020 REVIEW ARTICLE Prostate Cancer Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging Daniela A. Ferraro, MD, and Irene A. Burger, MD association of prostate-specific membrane antigen (PSMA) PET and Abstract: Positron-emission tomography (PET) with prostate-specific MRI is very interesting due to the combination of superior assess- membrane antigen (PSMA) has been increasingly used to image prostate ment of the primary tumor by MRI over CT and the improved cancer in the last decade. In the staging setting several studies have already assessment of pelvic nodes and distant metastases by PSMA PET. been published suggesting PSMA PET can be a valuable tool. They, however, Despite the high cost of the examination and the low availability did not translate into recommendations by guidelines. Both PSMA PET/ of PET/MRI scanners, several original studies have been published in computed tomography (CT) and PET/magnetic resonance imaging have been the last years regarding PSMA PET/MRI for staging. Even though investigated in the staging setting, showing higher detection rate of prostate there is still a lack of literature showing a higher impact on patient cancer lesions over the conventional imaging work-up and some studies
Topics in Magnetic Resonance Imaging – Wolters Kluwer Health
Published: Feb 1, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.